CIITA: Difference between revisions
CSV import |
CSV import |
||
| Line 31: | Line 31: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 06:15, 17 March 2025
CIITA (Class II Major Histocompatibility Complex Transactivator) is a protein that in humans is encoded by the CIITA gene. CIITA is a key regulator in the immune system, specifically in the expression of the Class II Major Histocompatibility Complex (MHC).
Function[edit]
CIITA is a transcription factor that regulates the expression of Class II MHC genes. The Class II MHC proteins are essential for the immune system's ability to present antigens to the T cells, a process known as antigen presentation. Without CIITA, the Class II MHC genes are not expressed, which can lead to a weakened immune response.
Structure[edit]
The CIITA protein is composed of several domains, each with a specific function. The N-terminal domain is involved in transcriptional activation, while the C-terminal domain is responsible for the protein's nuclear localization. The central region of the protein contains a proline-rich domain and a leucine-rich repeat (LRR) domain, which are thought to be involved in protein-protein interactions.
Clinical significance[edit]
Mutations in the CIITA gene can lead to a rare immunodeficiency disorder known as Bare Lymphocyte Syndrome type II (BLS II). This condition is characterized by a lack of MHC Class II expression, leading to severe combined immunodeficiency.
See also[edit]
References[edit]
<references />
